Deals & Matters

Foley Hoag Advises LigaChem Biosciences in Two Exclusive Worldwide Antibody Licensing Deals with NovaRock Biotherapeutics for ADC Drug Development

June 27, 2025

Foley Hoag advised LigaChem Biosciences, a clinical-stage biotech company, in two worldwide in-licensing transactions for novel antibodies from NovaRock Biotherapeutics.  LigaChem Biosciences secured the exclusive rights to develop and commercialize antibody drug conjugates (ADC) incorporating these antibodies.

Foley Hoag attorneys Sarah Cooleybeck, Sumi Sedor and Aaron Feng, with assistance from Lucas Watkins and Alison Bauer, represented LigaChem Biosciences in these transactions.  

More information on these deals can be found here.